Drug Development

Articles

The vaccine is 66% effective overall in preventing moderate to severe COVID-19 28 days after vaccination.

J&J’s COVID-19 Vaccine Candidate Effective in Preventing Moderate to Severe COVID-19

The vaccine met the primary endpoint with a vaccine efficacy of 89.3% in its Phase III trial in the United Kingdom and a vaccine efficacy of 49% in HIV-positive participants and 60% in HIV-negative participants in a South African Phase IIb trial. 

Novavax Shares Data from UK and South Africa COVID-19 Vaccine Candidate Trials 

The dispute between the European Commission (EC) of the European Union and pharmaceutical company AstraZeneca continues.



Vaccine Supply Dispute Between EU and AstraZeneca Continues

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.

Balancing Innovation Protection and Affordability

The project is aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.

BioMed X Launches Drug Delivery Research Project with Janssen

Sanofi will offer access to its infrastructure and expertise to help BioNTech produce over 125 million doses of its COVID-19 vaccine in Europe.

Sanofi to Help Manufacture and Supply BioNTech’s COVID-19 Vaccine

The companies have entered into an advance purchase agreement with COVAX to provide up to 40 million doses of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, to lower-middle-income countries.

Pfizer and BioNTech Enter into Agreement with COVAX for COVID-19 Vaccine Delivery 

The company is discontinuing the development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, to focus on advancing its two SARS-CoV-2/COVID-19 therapeutic candidates, MK-4482 and MK-7110. 

Merck Halts Development of its COVID-19 Vaccine Candidates

The drug offers immediate post-exposure protection against the virus and will serve as a counterpart to the vaccine during its early phases.

Grifols Initiates Trial for New COVID-19 Drug

Paul S. Larson, MD, paul.larson@ucsf.edu, is professor and vice-chair of Neurological Surgery at the University of California San Francisco, chief of Neurosurgery at the San Francisco Veterans Affairs Medical Center, and surgical director of the Parkinson’s Disease Research, Education and Clinical Center.

Leveraging real-time MRI guidance for intracranial gene therapy administration potentially improves efficacy and outcomes.

Formulation and Drug Delivery